Future clinical trials should explore the optimal safe use of G-CSF in patients treated with CAR T. Until then, our results suggest a strategy where G-CSF is used after CAR T as a treatment for severe neutropenia as opposed to prophylaxis prior to CAR T could be associated with less severe CRS. Here, CSF3 is linked to Decreased total neutrophil count.